CD22-directed monoclonal antibody therapy for lymphoma (Q35206354)

7 August 2017

1 reference

title

CD22-directed monoclonal antibody therapy for lymphoma (English)

1 reference

7 August 2017

1 reference

Abby B Siegel

1

1 reference

7 August 2017

David M Goldenberg

2

1 reference

7 August 2017

Alessandra Cesano

3

1 reference

7 August 2017

Morton Coleman

4

1 reference

7 August 2017

John P Leonard

5

1 reference

7 August 2017

publication date

1 August 2003

1 reference

7 August 2017

1 reference

7 August 2017

volume

30

1 reference

7 August 2017

issue

4

1 reference

7 August 2017

page(s)

457-464

1 reference

Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype Antibody

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900240-9

7 January 2021

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900240-9

7 January 2021

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900240-9

7 January 2021

Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900240-9

7 January 2021

European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900240-9

7 January 2021

Treatment of Waldenström's macroglobulinemia with rituximab

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900240-9

7 January 2021

CD20-Directed Serotherapy in Patients With Multiple Myeloma: Biologic Considerations and Therapeutic Applications

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900240-9

7 January 2021

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900240-9

7 January 2021

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900240-9

7 January 2021

Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900240-9

7 January 2021

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900240-9

7 January 2021

Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900240-9

7 January 2021

The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900240-9

7 January 2021

Radioimmunotherapy of B-Cell Lymphoma with [131I]Anti-B1 (Anti-CD20) Antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900240-9

7 January 2021

Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900240-9

7 January 2021

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900240-9

7 January 2021

A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900240-9

7 January 2021

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900240-9

7 January 2021

Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900240-9

7 January 2021

Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2.

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900240-9

7 January 2021

Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900240-9

7 January 2021

Phase I/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900240-9

7 January 2021

Phase II Trial of Remitogen™ (Humanized 1D10) Monoclonal Antibody Targeting Class II in Patients with Relapsed Low-Grade or Follicular Lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900240-9

7 January 2021

Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900240-9

7 January 2021

In vitro anti-tumour activity of anti-CD80 and anti-CD86 immunotoxins containing type 1 ribosome-inactivating proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900240-9

7 January 2021

Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900240-9

7 January 2021

CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling.

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900240-9

7 January 2021

Association of CD22 with the B cell antigen receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900240-9

7 January 2021

The amino-terminal immunoglobulin-like domain of sialoadhesin contains the sialic acid binding site. Comparison with CD22.

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900240-9

7 January 2021

Regulation of CD45 engagement by the B-cell receptor CD22.

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900240-9

7 January 2021

Sialoadhesin, myelin-associated glycoprotein and CD22 define a new family of sialic acid-dependent adhesion molecules of the immunoglobulin superfamily

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900240-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900240-9

1 reference

7 January 2021

Internalization and intracellular processing of an anti-B-cell lymphoma monoclonal antibody, LL2

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900240-9

7 January 2021

Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22.

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900240-9

7 January 2021

Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents: a new generation of therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900240-9

7 January 2021

Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900240-9

7 January 2021

10.1016/S0093-7754(03)00240-9

Identifiers

DOI

1 reference

7 August 2017

1 reference